Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients (CeTeG)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Ulrich Herrlinger, University Hospital, Bonn
ClinicalTrials.gov Identifier:
NCT01149109
First received: June 14, 2010
Last updated: October 27, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: February 2015
  Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)